About T-cell surface glycoprotein CD1e, membrane-associated
T-cell surface glycoprotein CD1e, membrane-associated (CD1E) is a protein
from Homo sapiens identified by UniProt accession
P15812, 388 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | T-cell surface glycoprotein CD1e, membrane-associated |
| UniProt accession | P15812 |
| Gene | CD1E |
| Organism | Homo sapiens |
| Length | 388 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- Guillain-Barre syndrome · score 0.07
- lung adenocarcinoma · score 0.06
- QRS duration · score 0.04
- COVID-19 · score 0.04
- sphingomyelin measurement · score 0.04
- mean corpuscular volume · score 0.03
- reticulocyte measurement · score 0.03
- neoplasm · score 0.02
- myeloid sarcoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15812-F1 | alphafold | PREDICTED | 81.52 | — |
Amino-acid sequence (388 residues)
MLLLFLLFEG LCCPGENTAA PQALQSYHLA AEEQLSFRML QTSSFANHSW AHSEGSGWLG DLQTHGWDTV LGTIRFLKPW SHGNFSKQEL KNLQSLFQLY FHSFIQIVQA SAGQFQLEYP FEIQILAGCR MNAPQIFLNM AYQGSDFLSF QGISWEPSPG AGIRAQNICK VLNRYLDIKE ILQSLLGHTC PRFLAGLMEA GESELKRKVK PEAWLSCGPS PGPGRLQLVC HVSGFYPKPV WVMWMRGEQE QRGTQRGDVL PNADETWYLR ATLDVAAGEA AGLSCRVKHS SLGGHDLIIH WGGYSIFLIL ICLTVIVTLV ILVVVDSRLK KQSSNKNILS PHTPSPVFLM GANTQDTKNS RHQFCLAQVS WIKNRVLKKW KTRLNQLW
Explore T-cell surface glycoprotein CD1e, membrane-associated with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets